Skip to content


Nova TheraNostics

Health & Medicine



Nova TheraNostics is developing a new and uniquely differentiated contrast agent for use with magnetic resonance imaging (MRI) that will not only be highly competitive relative to existing agents, but will also enable the extension of MRI into new indications not currently served by this imaging modality. NTN’s contrast agent, Nanobrite™, will be the only gadolinium-based contrast agent (GBCA) capable of serving some of these new MRI diagnostic indications, garnering for itself a large, new, captive market in addition to significant penetration of the existing GBCA market.

Team Members

John R. Reddington

DVM, PhD, CEO (interim)

Craig W. Philips

MBA, Chief Operation Officer, and Entrepreneur-In-Residence, UW CoMotion

Udo Schmiedl, MD, PhD

Chief Medical Officer and Radiologist, Swedish Medical Center

Eric Blackstone

PhD, MBA, VP Operations

Dr. Rodney Ho

Cofounder and Professor of Pharmaceutics